C. Randal Mills Biography and Net Worth

President & CEO of Elutia

Dr. Randy Mills, Ph.D., co-founder of Elutia, has served as a member of Elutia’s board of directors since November 2015. Randy and Kevin Rakin started Elutia with the vision to build a regenerative medicine company to improve the lives of patients by developing a pipeline of cutting-edge biosurgical products.

Dr. Mills is an internationally recognized expert in regenerative medicine who has led pioneering biotechnology organizations that have created more than $1 billion in shareholder value for investors. As CEO of Osiris Therapeutics (Nasdaq: OSIR), he commercialized five cell-therapy products responsible for $1.5 billion in sales and led the company through an IPO that increased shareholder value 41-fold. Osiris was eventually sold to Smith and Nephew for $660 million. Dr. Mills was also a co-founder and officer of Regeneration Technologies (Nasdaq: RTIX), where he led operations, R&D, regulatory and business development through its successful IPO.

Randy’s ‘patient first’ leadership style has also helped transform some of the nation’s most respected medical institutions. As president of the California Institute for Regenerative Medicine, he radically improved the speed and transparency of the $3 billion agency. As CEO of the National Marrow Donor Program/Be The Match, he launched a bold plan to democratize cell therapy, resulting in significantly more bone marrow matches for ethnically diverse patients.

A sought-after speaker, Randy’s accomplishments have been chronicled in the Wall Street Journal, The New York Times, Forbes, and LA Times. He has also appeared on CNBC, Fox Business News, and Bloomberg. Randy has received numerous recognitions, including being named an Ernst & Young Entrepreneur of the Year, listed as one of the World’s 50 Most Influential People in Regenerative Medicine, and awarded winner of AATB’s Hyatt Memorial Award for Scientific Leadership in Transplantation.

Dr. Mills holds a Ph.D. in Pharmaceutical Science and a B.S. in Microbiology from the University of Florida and completed an internship in Clinical Pathology at Shands Hospital at the University of Florida. He is married with two children and is an avid pilot.

What is C. Randal Mills' net worth?: The estimated net worth of C. Randal Mills is at least $307.16 thousand as of December 17th, 2025. Dr. Mills owns 379,204 shares of Elutia stock worth more than $307,155 as of September 29th. This net worth evaluation does not reflect any other investments that Dr. Mills may own. Learn More about C. Randal Mills' net worth.
How do I contact C. Randal Mills?: The corporate mailing address for Dr. Mills and other Elutia executives is 12510 Prosperity Drive, Suite 370, Silver Spring, MD, 20904. Elutia can also be reached via phone at (240) 247-1143 and via email at [email protected]. Learn More on C. Randal Mills' contact information.
Has C. Randal Mills been buying or selling shares of Elutia?: C. Randal Mills has not been actively trading shares of Elutia in the last ninety days. Most recently, on Wednesday, December 17th, C. Randal Mills bought 3,000 shares of Elutia stock. The stock was acquired at an average cost of $0.51 per share, with a total value of $1,530.00. Following the completion of the transaction, the chief executive officer now directly owns 379,204 shares of the company's stock, valued at $193,394.04. Learn More on C. Randal Mills' trading history.
Who are Elutia's active insiders?: Elutia's insider roster includes Thomas Englese (Insider), Matthew Ferguson (CFO), Ronald Lloyd (CEO), Brigid Makes (Director), C. Randal Mills (President & CEO), and Kevin Rakin (Director). Learn More on Elutia's active insiders.
Are insiders buying or selling shares of Elutia?: In the last year, Elutia insiders bought shares 13 times. They purchased a total of 299,500 shares worth more than $220,810.00. The most recent insider tranaction occured on January, 30th when Director Guido J Neels bought 20,000 shares worth more than $20,800.00. Insiders at Elutia own 17.8% of the company. Learn More about insider trades at Elutia.
Information on this page was last updated on 1/30/2026.

C. Randal Mills Insider Trading History at Elutia

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/17/2025	Buy	3,000	$0.51	$1,530.00	379,204
11/24/2025	Buy	5,000	$0.60	$3,000.00	358,785
11/13/2025	Buy	13,500	$0.75	$10,125.00	353,785

C. Randal Mills Buying and Selling Activity at Elutia

Elutia Company Overview

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Today's Range

Now: $0.81

$0.81

$0.83

50 Day Range

MA: $0.87

$0.79

$1.01

2 Week Range

Now: $0.81

$0.50

$1.39

Volume

5,640 shs

Average Volume

31,025 shs

Market Capitalization

$35.87 million

P/E Ratio

0.85

Dividend Yield

N/A

Beta

0.88